Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Doll

Showing results (211-220 of 234) with videos related to

Pageof 24
Sort By:
Journal of Medicinal Chemistry|August 23, 2002
Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferaseArthur G Taveras, Cynthia Aki, Jianping Chao, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitorsMichael P Dwyer, Kamil Paruch, Carmen Alvarez, et al.
Biopolymers|October 17, 2007
Structure-guided discovery of cyclin-dependent kinase inhibitorsThierry O Fischmann, Alan Hruza, José S Duca, et al.
Bioorganic & Medicinal Chemistry|January 1, 1997
Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl protein transferaseF G Njoroge, R J Doll, B Vibulbhan, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitorsZhaoyang Meng, Bheemashankar A Kulkarni, Angela D Kerekes, et al.
Journal of Medicinal Chemistry|December 7, 2010
Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposureAngela D Kerekes, Sara J Esposite, Ronald J Doll, et al.
Bioorganic & Medicinal Chemistry Letters|March 17, 2018
Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitorTao Yu, Yonglian Zhang, Angela D Kerekes, et al.
British Journal of Clinical Pharmacology|June 24, 2026
Sustained pharmacodynamic effects of S-ketamine on cortical excitability and resting-state brain activity: A randomized, placebo-controlled trialCatherine M K E de Cuba, Annika A de Goede, Joost C van Mechelen, et al.
Bioorganic & Medicinal Chemistry|May 1, 1997
Detection and structural characterization of ras oncoprotein-inhibitors complexes by electrospray mass spectrometryA K Ganguly, B N Pramanik, E C Huang, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude miceM Liu, M S Bryant, J Chen, et al.
Pageof 24

Showing results (211-220 of 234) with videos related to

Sort By:
Pageof 24
Journal of Medicinal Chemistry|August 23, 2002
Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferaseArthur G Taveras, Cynthia Aki, Jianping Chao, et al.
Bioorganic & Medicinal Chemistry Letters|October 2, 2007
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitorsMichael P Dwyer, Kamil Paruch, Carmen Alvarez, et al.
Biopolymers|October 17, 2007
Structure-guided discovery of cyclin-dependent kinase inhibitorsThierry O Fischmann, Alan Hruza, José S Duca, et al.
Bioorganic & Medicinal Chemistry|January 1, 1997
Discovery of novel nonpeptide tricyclic inhibitors of Ras farnesyl protein transferaseF G Njoroge, R J Doll, B Vibulbhan, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitorsZhaoyang Meng, Bheemashankar A Kulkarni, Angela D Kerekes, et al.
Journal of Medicinal Chemistry|December 7, 2010
Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposureAngela D Kerekes, Sara J Esposite, Ronald J Doll, et al.
Bioorganic & Medicinal Chemistry Letters|March 17, 2018
Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitorTao Yu, Yonglian Zhang, Angela D Kerekes, et al.
British Journal of Clinical Pharmacology|June 24, 2026
Sustained pharmacodynamic effects of S-ketamine on cortical excitability and resting-state brain activity: A randomized, placebo-controlled trialCatherine M K E de Cuba, Annika A de Goede, Joost C van Mechelen, et al.
Bioorganic & Medicinal Chemistry|May 1, 1997
Detection and structural characterization of ras oncoprotein-inhibitors complexes by electrospray mass spectrometryA K Ganguly, B N Pramanik, E C Huang, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude miceM Liu, M S Bryant, J Chen, et al.
Pageof 24